Prudential Financial’s Spyre Therapeutics SYRE Stock Holding History

Prudential Financial’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.76M	Buy	87,370 +27,815	+47%	+$2.03M	0.01%	807
2026 Q1	$3M	Buy	+59,555	New	+$2.25M	﹤0.01%	1139
2023 Q1	–	Sell	-688	Closed	-$7.74K	–	2672
2022 Q4	$7.74K	Buy	+688	New	+$12.4K	﹤0.01%	2584
2020 Q4	–	Sell	-632	Closed	-$112K	–	2500
2020 Q3	$112K	Sell	632 -382	-38%	-$70.7K	﹤0.01%	2361
2020 Q2	$234K	Sell	1,014 -209	-17%	-$39.8K	﹤0.01%	2201
2020 Q1	$142K	Sell	1,223 -128	-9%	-$21.8K	﹤0.01%	2226
2019 Q4	$258K	Sell	1,351 -8	-0.6%	-$1.57K	﹤0.01%	2262
2019 Q3	$261K	Buy	1,359 +415	+44%	+$80.8K	﹤0.01%	2245
2019 Q2	$162K	Buy	+944	New	+$163K	﹤0.01%	2363

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Prudential Financial's SYRE Position: Q2 2026 in Review

Prudential Financial increased its Spyre Therapeutics (SYRE) stake by 47% in Q2 2026, buying an estimated $2.03M and bringing the position to 87,370 shares worth $7.76M. The position accounts for 0.01% of the portfolio, ranked #807.

Prudential Financial first reported a position in SYRE in Q2 2019 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Prudential Financial held 87,370 shares of Spyre Therapeutics worth $7.76M as of Q2 2026.
Prudential Financial bought 27,815 Spyre Therapeutics shares in Q2 2026, an estimated $2.03M.
Spyre Therapeutics made up 0.01% of Prudential Financial's portfolio in Q2 2026, its #807 holding.
Prudential Financial first reported a position in Spyre Therapeutics in Q2 2019 and has held it in 9 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.